Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
نویسندگان
چکیده
منابع مشابه
Certolizumab pegol for the treatment of rheumatoid arthritis.
INTRODUCTION Improved understanding of the pathogenesis of rheumatoid arthritis (RA), and subsequent development of targeted therapies, have greatly advanced the management of this chronic inflammatory disease. The aim of treatment is a state of clinical remission. Certolizumab pegol (CZP) is a novel pegylated TNF alpha inhibitor (TNFi) therapy and is the focus of this review. AREAS COVERED C...
متن کاملCertolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of certolizumab pegol (CZP) for adults with active rheumatoid arthritis (RA) that have not responded adequately to treatment with conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX), in accordance with the licensed indication, based...
متن کاملPrefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis
A new anti-tumor necrosis factor alpha (TNF-α) inhibitor with a novel mechanism of action has entered phase 3 trials in rheumatoid arthritis (RA). Certolizumab pegol (Cimzia(®)) is a humanized Fab' antibody fragment against TNF-α with a polyethylene glycol tail that prevents complement-dependent and antibody-dependent cell-mediated cytotoxicity or apoptosis. Four randomized clinical trials have...
متن کاملCertolizumab pegol for rheumatoid arthritis: effective in combination with methotrexate or as monotherapy
Rheumatoid arthritis (RA) is estimated to affect 5 million people worldwide [1] with 0.3–1% of the population in industrialized countries suffering from RA [2]. The development of RA is associated with increasing age and female gender, with the prevalence among women being approximately two-times greater than in men [3]. Although the etiology of RA remains unclear, the inflammation and joint da...
متن کاملTargeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's disease. Crohn's disease is initiated by an innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profile. Several new treatments now focus on suppressing T-cell differentiation or T-cell inflammation. Sin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2017
ISSN: 1465-1858
DOI: 10.1002/14651858.cd007649.pub4